[HTML][HTML] Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
JE Axelrad, S Lichtiger, V Yajnik - World journal of …, 2016 - ncbi.nlm.nih.gov
In patients with inflammatory bowel disease (IBD), chronic inflammation is a major risk factor
for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated …
for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated …
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Modulating immune inhibitory pathways has been a major recent breakthrough in cancer
treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 …
treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 …
The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma
M Del Castillo, FA Romero, E Argüello… - Clinical Infectious …, 2016 - academic.oup.com
The risk of infection among patients receiving immune checkpoint blockade is unknown. We
retrospectively reviewed medical records of 740 patients with melanoma who received …
retrospectively reviewed medical records of 740 patients with melanoma who received …
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
V Sibaud, N Meyer, L Lamant, E Vigarios… - Current opinion in …, 2016 - journals.lww.com
Dermatologic complications of anti-PD-1/PD-L1 immune checkpo... : Current Opinion in
Oncology Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies …
Oncology Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies …
Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options
Methods| This study was reviewed and approved by the institutional review board of the
University of Texas Southwestern Medical Center (STU 082012-040) and a waiver of …
University of Texas Southwestern Medical Center (STU 082012-040) and a waiver of …
[HTML][HTML] Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Immune checkpoint inhibitors such as ipilimumab and nivolumab improve survival in
patients with advanced melanoma and are increasingly available to clinicians for use in the …
patients with advanced melanoma and are increasingly available to clinicians for use in the …
Immune-related adverse events associated with immune checkpoint inhibitors
D Day, AR Hansen - BioDrugs, 2016 - Springer
Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown …
associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown …
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
The recent success of immune checkpoint blockade in cancer therapy illustrates the
importance of the inhibitory receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) …
importance of the inhibitory receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) …
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
LM Yshii, CM Gebauer, B Pignolet, E Maure… - Brain, 2016 - academic.oup.com
CTLA4 is an inhibitory regulator of immune responses. Therapeutic CTLA4 blockade
enhances T cell responses against cancer and provides striking clinical results against …
enhances T cell responses against cancer and provides striking clinical results against …
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over
the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and …
the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and …